- Home
- RIGL vs ITOS Comparison
RIGL vs ITOS Comparison
Compare RIGL & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- ITOS
- Stock Information
- Founded
- RIGL 1996
- ITOS 2011
- Country
- RIGL United States
- ITOS United States
- Employees
- RIGL N/A
- ITOS N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RIGL Health Care
- ITOS Health Care
- Exchange
- RIGL Nasdaq
- ITOS Nasdaq
- Market Cap
- RIGL 335.5M
- ITOS 381.2M
- IPO Year
- RIGL 2000
- ITOS 2020
- Fundamental
- Price
- RIGL $21.91
- ITOS $10.09
- Analyst Decision
- RIGL Buy
- ITOS Hold
- Analyst Count
- RIGL 5
- ITOS 6
- Target Price
- RIGL $36.40
- ITOS $10.60
- AVG Volume (30 Days)
- RIGL 182.1K
- ITOS 1.5M
- Earning Date
- RIGL 08-05-2025
- ITOS 08-11-2025
- Dividend Yield
- RIGL N/A
- ITOS N/A
- EPS Growth
- RIGL N/A
- ITOS N/A
- EPS
- RIGL 2.08
- ITOS N/A
- Revenue
- RIGL $203,077,000.00
- ITOS $35,000,000.00
- Revenue This Year
- RIGL $14.41
- ITOS N/A
- Revenue Next Year
- RIGL $15.97
- ITOS N/A
- P/E Ratio
- RIGL $10.11
- ITOS N/A
- Revenue Growth
- RIGL 70.16
- ITOS 177.89
- 52 Week Low
- RIGL $8.61
- ITOS $4.80
- 52 Week High
- RIGL $29.82
- ITOS $18.13
- Technical
- Relative Strength Index (RSI)
- RIGL 66.30
- ITOS 52.39
- Support Level
- RIGL $19.51
- ITOS $10.10
- Resistance Level
- RIGL $21.41
- ITOS $10.16
- Average True Range (ATR)
- RIGL 0.88
- ITOS 0.10
- MACD
- RIGL 0.24
- ITOS -0.05
- Stochastic Oscillator
- RIGL 96.45
- ITOS 0.00
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.